New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
Key Highlights
- ➤Omvoh achieved comprehensive disease control in 27.7% of ulcerative-colitis patients versus 14% placebo
- ➤Omvoh achieved corticosteroid-free deep remission in 20.4% of Crohn’s patients versus 2% placebo
- ➤Prior biologic failure patients achieved Omvoh remission rates of 23.4% in UC and 15.7% in Crohn’s
- ➤Omvoh-treated patients achieving composite endpoints reported higher IBDQ remission and quality of life
Expert Statements
Anabela Cardoso, Senior vice president, Lilly Immunology Medical Affairs
“Treatment in inflammatory bowel disease is often measured one endpoint at a time. These new data show that patients treated with Omvoh achieved multiple treatment goals simultaneously at one year, including those with prior biologic failure, and were more likely to report better quality of life”
Anabela Cardoso, Senior vice president, Lilly Immunology Medical Affairs
“These findings reinforce the impact that Omvoh can have for people living with ulcerative colitis and Crohn's disease and show that a higher bar for disease control is achievable.”
Stefan Schreiber, M.D., University Hospital Schleswig-Holstein, Christian-Albrecht University of Kiel
“Inflammatory bowel disease is complex, and understanding treatment impact requires a broader view than any single endpoint can provide. These endpoints reflect a meaningful shift in how we define treatment success”
Stefan Schreiber, M.D., University Hospital Schleswig-Holstein, Christian-Albrecht University of Kiel
“Across the LUCENT and VIVID programs, Omvoh-treated patients achieved multidimensional treatment outcomes, including comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease. Importantly, these outcomes were also observed in patients with prior biologic failure.”
New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year PR Newswire
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use
Get started
Create a free account to read the full story.